Moderna opts for licensing deal with Avacta for its biotherapeutics and reagents

Laboratory
Moderna has opted to enter a licensing deal with U.K.-based Avacta Group to use the U.K.-based company’s Affimer biotherapeutics and reagents. (Getty/RossHelen)

Moderna has opted to enter a licensing deal with U.K.-based Avacta Group to use the U.K.-based company’s Affimer biotherapeutics and reagents.

The two began collaborating in 2015 that gave Moderna exclusive access to the Affimra tech for certain collaboration targets. The deal also included the option to enter into exclusive license agreements.

Under terms of the latest agreement, Avacta could receive undisclosed payments upon reaching future clinical development milestones and royalties that are part of potential product sales.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“This is further strong validation of the potential of the Affimer drug platform to generate differentiated therapeutic molecules for development,” Dr. Alastair Smith, Avacta’s chief executive, said in a statement. “We will continue to support Moderna and their development objectives and I look forward to updating the market as and when key development milestones are met.”

Avacta’s Affimer reagents and therapeutics are a class of non-antibody binding proteins that have been designed for a wide variety of uses where antibodies and aptamers have limitations, according to the company’s website. The technology can be used to detect difficult targets.

Moderna, which posted a blockbuster $604 million IPO in December, boasts a core technology that uses mRNA to trigger the production of human proteins with patient cells, creating what the company has described as an in vivo“factory” for target therapies.

Suggested Articles

Qiagen is collaborating with Ares Genetics to develop new bioinformatics and assay solutions for research targeting antibiotic-resistant bacteria.

STA Pharmaceutical has signed an exclusive technology and marketing deal with Swiss biotech BioLingus.

Clinerion is partnering with Citeline to give clinical researchers a more comprehensive approach to making evidence-based decisions.